Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Development And Characterization Of A Tacrolimus/hydroxypropyl-β-cyclodextrin Eye Drop

  • Bermúdez, María José
  • Varela-Fernández, Rubén
  • García-Otero, Xurxo
  • Díaz Tomé, Victoria
  • Martín-Pastor, Manuel
  • González-Barcia, Miguel
  • Blanco Méndez, José
  • Mondelo-García, Cristina
  • González, Francisco
  • Aguiar, Pablo
  • Fernández Ferreiro, Anxo
  • Otero Espinar, Francisco Javier
[Abstract] Uveitis is a vision inflammatory disorder with a high prevalence in developing countries. Currently, marketed treatments remain limited and reformulation is usually performed to obtain a tacrolimus eye drop as a therapeutic alternative in corticosteroid-refractory eye disease. The aim of this work was to develop a mucoadhesive, non-toxic and stable topical ophthalmic formulation that can be safely prepared in hospital pharmacy departments. Four different ophthalmic formulations were prepared based on the tacrolimus/hydroxypropyl-β-cyclodextrin (HPβCD) inclusion complexes’ formation. Phase solubility diagrams, Nuclear Magnetic Resonance (NMR) and molecular modeling studies showed the formation of 1:1 and 1:2 tacrolimus/HPβCD inclusion complexes, being possible to obtain a 0.02% (w/v) tacrolimus concentration by using 40% (w/v) HPβCD aqueous solutions. Formulations also showed good ophthalmic properties in terms of pH, osmolality and safety. Stability studies proved these formulations to be stable for at least 3 months in refrigeration. Ex vivo bioadhesion and in vivo ocular permanence showed good mucoadhesive properties with higher ocular permanence compared to the reference pharmacy compounding used in clinical settings (t1/2 of 86.2 min for the eyedrop elaborated with 40% (w/v) HPβCD and Liquifilm® versus 46.3 min for the reference formulation). Thus, these novel eye drops present high potential as a safe alternative for uveitis treatment, as well as a versatile composition to include new drugs intended for topical ophthalmic administration., This research was partially supported by the Spanish Ministry of Science, Innovation and Universities (RTI2018-099597-B-100), the ISCIII (PI17/00940, RETICS Oftared, RD16/0008/0003 and RD12/0034/0017) and by Xunta de Galicia, grant numbers GPC2013/015 and GRC2017/015. X.G.-O. and R.V.-F. acknowledge the financial support of the IDIS (Health Research Institute of Santiago de Compostela) (predoctoral research fellowships). P.A. acknowledges the support of RYC-2015/17430 (Ramón y Cajal). A.F.-F. acknowledges the support received from the Instituto de Salud Carlos III (ISCIII) through its Juan Rodes grant (JR18/00014)., Xunta de Galicia; GPC2013/015, Xunta de Galicia; GRC2017/015